Valeritas Holdings Inc (NASDAQ: VLRX) rose Wednesday after the company announced data from its V-Go device was published in a peer reviewed journal.
The company, based out of Bridgewater, New Jersey, is the maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes.
Today, it announced the publication this week of a manuscript titled “Clinical and Economic Considerations Based on Persistency with a Novel Insulin Delivery Device versus Conventional Insulin Delivery in Patients with Type 2 Diabetes: A Retrospective Analysis” in Research and Social Administrative Pharmacy, an international, peer-reviewed journal.
Insulin delivery options have advanced over the years, but questions remain regarding whether persistent use of these latest innovations offers benefits over the conventional insulin delivery (CID) methods of insulin pen devices or insulin syringes.
This study demonstrated when patients were persistent using V-Go, clinical outcomes were significantly improved compared to patients who returned to CID methods after trialing V-Go.
One of the lead investigators behind the study said, "We are very encouraged with both the clinical and economic benefits patients experienced in our study while utilizing V-Go to manage their diabetes.
"In my opinion, great consideration should be given to the use of V-Go for the management of patients requiring insulin therapy, given the improvements over conventional insulin delivery in glycemic control and economic outcomes."
Share prices gained nine cents, or 6.2%, Wednesday morning to $1.54
